Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, et al. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023;83(6):486-494.

Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, et al. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023;7:e2200334.

Camilleri AE, Cung M, Hart FM, Pagovich OE, Crystal RG, Greenblatt MB, et al. Gene Therapy to Treat Osteopenia Associated With Chronic Ethanol Consumption and Aldehyde Dehydrogenase 2 Deficiency. JBMR Plus. 2023;7(4):e10723.

Utsumi T, Yamada Y, Diaz-Meco MT, Moscat J, Nakanishi Y. Sessile serrated lesions with dysplasia: is it possible to nip them in the bud? J Gastroenterol. 2023;58(8):705-717.

Singh B, Dopkins N, Fei T, Marston JL, Michael S, Reyes-Gopar H, et al. Locus specific human endogenous retroviruses reveal new lymphoma subtypes. bioRxiv. 2023.

Simner PJ, Bard JD, Doern C, J Johnson K, Westblade L, Yenokyan G, et al. Reporting of Antimicrobial Resistance from Blood Cultures, an Antibacterial Resistance Leadership Group Survey Summary: Resistance Marker Reporting Practices from Positive Blood Cultures. Clin Infect Dis. 2023;76(9):1550-1558.

Yang HS, Wang F, Greenblatt MB, Huang SX, Zhang Y. AI Chatbots in Clinical Laboratory Medicine: Foundations and Trends. Clin Chem. 2023;69(11):1238-1246.

Potter RF, Zhang K, Reimler B, Marino J, Muenks CE, Alvarado K, et al. Uncharacterized and lineage-specific accessory genes within the Proteus mirabilis pan-genome landscape. mSystems. 2023;8(4):e0015923.

Limberg J, Lee-Saxton YJ, Egan CE, AlAnazi AA, Easthausen I, Stefanova D, et al. Perineural Invasion in Papillary Thyroid Cancer: A Rare Indicator of Aggressive Disease. Ann Surg Oncol. 2023;30(6):3570-3577.

Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Chen X, Socciarelli F, et al. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. bioRxiv. 2023.